MOORESTOWN, N.J., Feb. 07, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a leader in providing technology and medication decision support services focused on enhancing medication safety for healthcare organizations, will release its fourth quarter and full year 2016 operating results on Monday, March 13, 2017 after market close, on the investor relations section of TRHC’s website at ir.trhc.com with a conference call hosted by TRHC’s management to follow at 5:00 p.m. EDT.
Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 844-413-0947 or 216-562-0423 for international callers, and referencing participant code 64870364 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of TRHC’s website at ir.trhc.com and an audio file of the call will also be archived and available for replay approximately two hours after the live event for a period of 90 days thereafter at ir.trhc.com. After the conference call, a replay will be available until April 12, 2017 and can be accessed by dialing 855-859-2056 or 404-537-3406 for international callers, and referencing participant code 64870364.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Since 2011, TRHC has focused on optimizing outcomes for PACE and other healthcare organizations through its unique Medication Risk Mitigation software and Medication Decision Support and Adherence tools that personalize each participant's medication regimen. For more information, please visit: www.TRHC.com.
Contact: Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected] Media Dianne Semingson [email protected] 215-870-0829


Italy Fines Apple €98.6 Million Over App Store Dominance
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



